Serum Cortisol, Nesfatin-1, and IL-1β: Potential Diagnostic Biomarkers in Elderly Patients with Treatment-Resistant Depression

References

• Kessler R, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc. 2009;18(1):23–33. doi:10.1017/s1121189x00001421
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–224. doi:10.1016/S2215-0366(18)30511-X
   PubMed Web of Science ®Google Scholar
• Al-Harbi K. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–388. doi:10.2147/PPA.S29716
   PubMed Web of Science ®Google Scholar
• McIntyre R, Filteau M, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7. doi:10.1016/j.jad.2013.10.043
   PubMed Web of Science ®Google Scholar
• Ng C, Kato T, Han C, et al. Definition of treatment-resistant depression - Asia Pacific perspectives. J Affect Disord. 2019;245:626–636. doi:10.1016/j.jad.2018.11.038
   PubMed Web of Science ®Google Scholar
• Rush A, Trivedi M, Wisniewski S, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.1905
   PubMed Web of Science ®Google Scholar
• Gibson T, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5):370–377.
   PubMed Web of Science ®Google Scholar
• Mosimann U, Marré S, Werlen S, et al. Antidepressant effects of repetitive transcranial magnetic stimulation in the elderly: correlation between effect size and coil-cortex distance. Arch Gen Psychiatry. 2002;59(6):560–561. doi:10.1001/archpsyc.59.6.560
   PubMed Web of Science ®Google Scholar
• Solé-Padullés C, Bartrés-Faz D, Junqué C, et al. Repetitive transcranial magnetic stimulation effects on brain function and cognition among elders with memory dysfunction. A randomized sham-controlled study. Cereb Cortex. 2006;16(10):1487–1493. doi:10.1093/cercor/bhj083
   PubMed Web of Science ®Google Scholar
• Proma M, Daria S, Nahar Z, Ashraful Islam S, Bhuiyan M, Islam M. Monocyte chemoattractant protein-1 levels are associated with major depressive disorder. J Basic Clin Physiol Pharmacol. 2022. doi:10.1515/jbcpp-2021-0132
   PubMedGoogle Scholar
• Riya S, Sultana S, Daria S, et al. Evaluation of serum lysophosphatidic acid and lysophosphatidylcholine levels in major depressive disorder patients. Cureus. 2020;12(12):e12388. doi:10.7759/cureus.12388
   PubMed Web of Science ®Google Scholar
• Daria S, Proma M, Shahriar M, Islam S, Bhuiyan M, Islam M. Serum interferon-gamma level is associated with drug-naïve major depressive disorder. SAGE Open Med. 2020;8:2050312120974169. doi:10.1177/2050312120974169
   Web of Science ®Google Scholar
• Ali S, Nahar Z, Rahman M, Islam S, Bhuiyan M, Islam M. Serum insulin-like growth factor-1 and relaxin-3 are linked with major depressive disorder. Asian J Psychiatr. 2020;53:102164. doi:10.1016/j.ajp.2020.102164
   PubMed Web of Science ®Google Scholar
• Islam M, Ali S, Karmoker J, et al. Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder. BMC Psychiatry. 2020;20(1):333. doi:10.1186/s12888-020-02738-2
   PubMed Web of Science ®Google Scholar
• Swaab D, Bao A, Lucassen P. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev. 2005;4(2):141–194. doi:10.1016/j.arr.2005.03.003
   PubMed Web of Science ®Google Scholar
• Strawbridge R, Young A, Cleare A. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr Dis Treat. 2017;13:1245–1262. doi:10.2147/NDT.S114542
   PubMed Web of Science ®Google Scholar
• Biggio F, Pisu M, Garau A, et al. Maternal separation attenuates the effect of adolescent social isolation on HPA axis responsiveness in adult rats. Eur Neuropsychopharmacol. 2014;24(7):1152–1161. doi:10.1016/j.euroneuro.2014.03.009
   PubMed Web of Science ®Google Scholar
• Maghsoudi N, Ghasemi R, Ghaempanah Z, Ardekani A, Nooshinfar E, Tahzibi A. Effect of chronic restraint stress on HPA axis activity and expression of BDNF and Trkb in the hippocampus of pregnant rats: possible contribution in depression during pregnancy and postpartum period. Basic Clin Neurosci. 2014;5(2):131–137.
   PubMedGoogle Scholar
• Xu Y, Ge J, Qin G, et al. Acute, but not chronic, stress increased the plasma concentration and hypothalamic mRNA expression of NUCB2/nesfatin-1 in rats. Neuropeptides. 2015;54:47–53. doi:10.1016/j.npep.2015.08.003
   PubMed Web of Science ®Google Scholar
• Strawbridge R, Carter B, Marwood L, et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry. 2019;214(1):42–51. doi:10.1192/bjp.2018.233
   PubMed Web of Science ®Google Scholar
• Ising M, Künzel H, Binder E, Nickel T, Modell S, Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):1085–1093. doi:10.1016/j.pnpbp.2005.03.014
   PubMed Web of Science ®Google Scholar
• Lang U, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31(6):761–777. doi:10.1159/000350094
   PubMed Web of Science ®Google Scholar
• Bali A, Singh N, Jaggi A. Neuropeptides as therapeutic targets to combat stress-associated behavioral and neuroendocrinological effects. CNS Neurol Disord Drug Targets. 2014;13(2):347–368. doi:10.2174/1871527313666140314163920
   PubMed Web of Science ®Google Scholar
• Xu Y, Ge J, Liang J, et al. Nesfatin-1 and cortisol: potential novel diagnostic biomarkers in moderate and severe depressive disorder. Psychol Res Behav Manag. 2018;11:495–502. doi:10.2147/PRBM.S183126
   PubMed Web of Science ®Google Scholar
• Ari M, Ozturk O, Bez Y, Oktar S, Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):497–500. doi:10.1016/j.pnpbp.2010.12.004
   PubMed Web of Science ®Google Scholar
• Xiao M, Li J, Jiang L, Shao H, Wang B. Plasma nesfatin-1 level is associated with severity of depression in Chinese depressive patients. BMC Psychiatry. 2018;18(1):88. doi:10.1186/s12888-018-1672-4
   PubMed Web of Science ®Google Scholar
• Korucu C, Atay İ, Zayıf S, Gültekin F. May nesfatin-1 be a state marker in major depressive disorder with suicidal ideation? Psychiatry Res. 2018;267:272–276. doi:10.1016/j.psychres.2018.05.086
   PubMed Web of Science ®Google Scholar
• Brenner R, Madhusoodanan S, Logiudice J, Castell G, MacKenzie T, O’Shaughnessy P. A comparison study of the turnaround time for telepsychiatry versus face-to-face consultations in general hospital nonpsychiatric emergency rooms. Ann Clin Psychiatry. 2020;32(1):12–16.
   PubMed Web of Science ®Google Scholar
• Sonsin-Diaz N, Gottesman R, Fracica E, et al. Chronic systemic inflammation is associated with symptoms of late-life depression: the ARIC Study. Am J Geriatr Psychiatry. 2020;28(1):87–98. doi:10.1016/j.jagp.2019.05.011
   PubMed Web of Science ®Google Scholar
• Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):445–450. doi:10.1016/j.pnpbp.2007.09.015
   PubMed Web of Science ®Google Scholar
• Chang H, Lee I, Gean P, et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun. 2012;26(1):90–95. doi:10.1016/j.bbi.2011.07.239
   PubMed Web of Science ®Google Scholar
• Amitai M, Taler M, Carmel M, et al. The relationship between plasma cytokine levels and response to selective serotonin reuptake inhibitor treatment in children and adolescents with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol. 2016;26(8):727–732. doi:10.1089/cap.2015.0147
   PubMed Web of Science ®Google Scholar
• Strawbridge R, Hodsoll J, Powell T, et al. Inflammatory profiles of severe treatment-resistant depression. J Affect Disord. 2019;246:42–51. doi:10.1016/j.jad.2018.12.037
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457. doi:10.1016/j.biopsych.2009.09.033
   PubMed Web of Science ®Google Scholar
• Ng A, Tam W, Zhang M, et al. IL-1β, IL-6, TNF- α and CRP in elderly patients with depression or Alzheimer’s disease: systematic review and meta-analysis. Sci Rep. 2018;8(1):12050.
   PubMed Web of Science ®Google Scholar
• Das R, Emon M, Shahriar M, et al. Higher levels of serum IL-1β and TNF-α are associated with an increased probability of major depressive disorder. Psychiatry Res. 2021;295:113568.
   PubMed Web of Science ®Google Scholar
• Zweig M, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–577. doi:10.1093/clinchem/39.4.561
   PubMed Web of Science ®Google Scholar
• Emon M, Das R, Nishuty N, Shalahuddin Qusar M, Bhuiyan M, Islam M. Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case-control study with or without antidepressant therapy. BMC Res Notes. 2020;13(1):83. doi:10.1186/s13104-020-04952-3
   PubMed Web of Science ®Google Scholar
• Das R, Emon M, Chowdhury S, Huque S, Zahan T, Islam M. Evaluation of serum glial cell line-derived neurotrophic factor in Bangladeshi major depressive disorder patients. Cureus. 2019;11(11):e6081. doi:10.7759/cureus.6081
   PubMed Web of Science ®Google Scholar
• Anjum S, Qusar M, Shahriar M, Islam S, Bhuiyan M, Islam M. Altered serum interleukin-7 and interleukin-10 are associated with drug-free major depressive disorder. Ther Adv Psychopharmacol. 2020;10:2045125320916655. doi:10.1177/2045125320916655
   Web of Science ®Google Scholar
• Nishuty N, Khandoker M, Karmoker J, et al. Evaluation of serum interleukin-6 and c-reactive protein levels in drug-naïve major depressive disorder patients. Cureus. 2019;11(1):e3868. doi:10.7759/cureus.3868
   PubMed Web of Science ®Google Scholar
• Islam M, Islam M, Ahmed I, et al. Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: a case-control study. SAGE Open Med. 2018;6:2050312118773953. doi:10.1177/2050312118773953
   Web of Science ®Google Scholar
• Islam M, Islam M, Shalahuddin Qusar M, et al. Alterations of serum macro-minerals and trace elements are associated with major depressive disorder: a case-control study. BMC Psychiatry. 2018;18(1):94. doi:10.1186/s12888-018-1685-z
   PubMed Web of Science ®Google Scholar
• Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry. 2017;22(4):527–536. doi:10.1038/mp.2016.120
   PubMed Web of Science ®Google Scholar
• Martiny K, Lunde M, Undén M, Dam H, Bech P. High cortisol awakening response is associated with an impairment of the effect of bright light therapy. Acta Psychiatr Scand. 2009;120(3):196–202. doi:10.1111/j.1600-0447.2009.01359.x
   PubMed Web of Science ®Google Scholar
• Juruena M, Pariante C, Papadopoulos A, Poon L, Lightman S, Cleare A. The role of mineralocorticoid receptor function in treatment-resistant depression. J Psychopharmacol. 2013;27(12):1169–1179. doi:10.1177/0269881113499205
   PubMed Web of Science ®Google Scholar
• Fischer S, King S, Papadopoulos A, Hotopf M, Young A, Cleare A. Hair cortisol and childhood trauma predict psychological therapy response in depression and anxiety disorders. Acta Psychiatr Scand. 2018;138(6):526–535. doi:10.1111/acps.12970
   PubMed Web of Science ®Google Scholar
• Jani B, McLean G, Nicholl B, et al. Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers. Front Hum Neurosci. 2015;9:18. doi:10.3389/fnhum.2015.00018
   PubMed Web of Science ®Google Scholar
• Jain F, Connolly C, Reus V, et al. Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: a retrospective analysis. Psychoneuroendocrinology. 2019;109:104386. doi:10.1016/j.psyneuen.2019.104386
   PubMed Web of Science ®Google Scholar
• Hinkelmann K, Moritz S, Botzenhardt J, et al. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study. Psychoneuroendocrinology. 2012;37(5):685–692. doi:10.1016/j.psyneuen.2011.08.012
   PubMed Web of Science ®Google Scholar
• Wei J, Sun G, Zhao L, et al. Analysis of hair cortisol level in first-episodic and recurrent female patients with depression compared to healthy controls. J Affect Disord. 2015;175:299–302. doi:10.1016/j.jad.2015.01.023
   PubMed Web of Science ®Google Scholar
• Schalla M, Unniappan S, Lambrecht N, Mori M, Taché Y, Stengel A. NUCB2/nesfatin-1 - Inhibitory effects on food intake, body weight and metabolism. Peptides. 2020;128:170308. doi:10.1016/j.peptides.2020.170308
   PubMed Web of Science ®Google Scholar
• Liu M, Shen X, Du X, Jiang H. Plasma levels of nesfatin-1 as a new biomarker in depression in Asians: evidence from meta-analysis. Biomarkers. 2020;25(3):228–234. doi:10.1080/1354750X.2020.1736157
   PubMed Web of Science ®Google Scholar
• Algul S, Ozcelik O. Evaluating the levels of nesfatin-1 and ghrelin hormones in patients with moderate and severe major depressive disorders. Psychiatry Investig. 2018;15(2):214–218. doi:10.30773/pi.2017.05.24
   PubMed Web of Science ®Google Scholar
• Karadeniz S, Yaman H, Bilginer Ç, Hızarcı Bulut S, Yaman S. Serum nesfatin-1, ghrelin, and lipid levels in adolescents with first episode drug naïve unipolar depression. Nord J Psychiatry. 2020;74(8):613–619. doi:10.1080/08039488.2020.1772363
   PubMed Web of Science ®Google Scholar
• Haroon E, Daguanno A, Woolwine B, et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology. 2018;95:43–49. doi:10.1016/j.psyneuen.2018.05.026
   PubMed Web of Science ®Google Scholar
• Chamberlain S, Cavanagh J, de Boer P, et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019;214(1):11–19. doi:10.1192/bjp.2018.66
   PubMed Web of Science ®Google Scholar
• Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare A. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 2015;25(10):1532–1543. doi:10.1016/j.euroneuro.2015.06.007
   PubMed Web of Science ®Google Scholar
• Sukoff Rizzo S, Neal S, Hughes Z, et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry. 2012;2:e199. doi:10.1038/tp.2012.120
   PubMed Web of Science ®Google Scholar
• Born J, Hansen K, Marshall L, Mölle M, Fehm H. Timing the end of nocturnal sleep. Nature. 1999;397(6714):29–30.
   PubMed Web of Science ®Google Scholar